Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases.

It is administered continuously until disease progression or intolerable toxicity [[6]]: patients discontinuing treatment due to either causes display significantly different survival rates, as those who stop the drug due to intolerance behave much better than those who discontinue because of disease progression or histologic transformation [[7]]. Ibrutinib is a first-generation oral BTK inhibitor approved for the treatment of patients with I de novo i or relapsed or refractory CLL [[4]]. Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder caused by the clonal proliferation and accumulation of small, mature-appearing CD5 SP + sp B-lymphocytes in the blood, bone marrow and lymphoid tissues [[1]]. Disease flare during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia. [Extracted from the article]